Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!

The management of axial spondyloarthritis (axSpA) has been completely transformed since the introduction of biologic therapies. Tumor necrosis factor inhibitors (TNFis) were the first effective drug therapies in people affected with axSpA who had previously failed to respond to nonsteroidal anti-inf...

Full description

Saved in:
Bibliographic Details
Main Authors: Concepcion Castillo-Gallego, Xabier Michelena, Helena Marzo-Ortega
Format: Article
Language:English
Published: SAGE Publishing 2020-01-01
Series:Indian Journal of Rheumatology
Subjects:
Online Access:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=5;spage=64;epage=70;aulast=Castillo-Gallego
Tags: Add Tag
No Tags, Be the first to tag this record!